PMD - Psychemedics Corp Stock Price, Fair Value and News

2.58USD+0.02 (+0.78%)Delayed

Market Summary

USD2.58+0.02

Delayed

0.78%

PMD Stock Price

View Fullscreen

PMD RSI Chart

PMD Valuation

Market Cap

15.0M

Price/Earnings (Trailing)

-3.36

Price/Sales (Trailing)

0.69

EV/EBITDA

-3.92

Price/Free Cashflow

-8.03

PMD Price/Sales (Trailing)

PMD Profitability

EBT Margin

-16.10%

Return on Equity

-70.98%

Return on Assets

-39.97%

Free Cashflow Yield

-12.45%

PMD Fundamentals

PMD Revenue

Revenue (TTM)

21.6M

Rev. Growth (Yr)

-8.57%

Rev. Growth (Qtr)

7.18%

PMD Earnings

Earnings (TTM)

-4.5M

Earnings Growth (Yr)

-79.17%

Earnings Growth (Qtr)

27.2%

Breaking Down PMD Revenue

Last 7 days

1.2%

Last 30 days

1.6%

Last 90 days

-13.1%

Trailing 12 Months

-48.3%

How does PMD drawdown profile look like?

PMD Financial Health

Current Ratio

1.48

PMD Investor Care

Dividend Yield

6.6%

Dividend/Share (TTM)

0.18

Shares Dilution (1Y)

1.48%

Diluted EPS (TTM)

-0.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	21.6M	0	0	0
2023	24.6M	23.6M	22.8M	22.1M
2022	25.7M	26.1M	26.0M	25.2M
2021	19.5M	22.3M	23.8M	24.9M
2020	35.4M	29.4M	24.7M	21.4M
2019	41.6M	40.1M	38.9M	37.7M
2018	40.4M	41.5M	42.5M	42.7M
2017	42.5M	42.5M	40.7M	39.7M
2016	26.9M	29.6M	34.4M	39.0M
2015	28.9M	28.2M	27.6M	27.0M
2014	27.5M	28.3M	28.9M	29.2M
2013	25.4M	25.4M	26.0M	26.9M
2012	24.3M	25.0M	25.1M	25.2M
2011	21.6M	22.5M	23.7M	24.1M
2010	0	18.0M	19.1M	20.1M
2009	0	0	0	17.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Psychemedics Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 17, 2023	weisenhoff michael	acquired	-	-	4,000	-
Aug 17, 2023	kamin peter	acquired	-	-	14,000	-
Aug 17, 2023	davis robyn c	acquired	-	-	14,000	-
Aug 17, 2023	reynolds andrew	acquired	-	-	14,000	-
Aug 17, 2023	nevin darius g	acquired	-	-	14,000	-
Aug 17, 2023	doucot charles m	sold	-59,182	4.66	-12,700	executive vice president
May 22, 2023	kubacki raymond c jr	sold (taxes)	-7,395	4.93	-1,500	chairman, ceo & president
May 22, 2023	schaffer michael i	sold (taxes)	-1,848	4.93	-375	vp of laboratory operations
May 22, 2023	doucot charles m	sold (taxes)	-4,067	4.93	-825	executive vice president
May 15, 2023	doucot charles m	sold (taxes)	-4,383	4.87	-900	executive vice president

Which funds bought or sold PMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Ancora Advisors LLC	sold off	-100	-231,393	-	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-106	10,259	-%
May 15, 2024	CRAWFORD INVESTMENT COUNSEL INC	reduced	-19.8	-12,264	47,225	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-9.00	-	-%
May 15, 2024	22NW, LP	unchanged	-	-8,232	804,045	0.69%
May 15, 2024	Tower Research Capital LLC (TRC)	added	31.19	2,052	8,922	-%
May 15, 2024	WEDBUSH SECURITIES INC	added	3.66	4,000	148,000	0.01%
May 15, 2024	RBF Capital, LLC	unchanged	-	-4,265	416,476	0.02%
May 15, 2024	Royal Bank of Canada	added	121	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	added	10.84	4,659	52,611	-%

Are Funds Buying or Selling PMD?

Are funds buying PMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PMD

No. of Funds

Unveiling Psychemedics Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	renaissance technologies llc	4.58%	265,563	SC 13G/A
Feb 02, 2024	kubacki raymond c jr	4.3%	246,737	SC 13G/A
Dec 14, 2023	powell anderson capital lp	5.38%	312,199	SC 13G
Feb 14, 2023	kubacki raymond c jr	6.5%	379,712	SC 13G/A
Feb 13, 2023	renaissance technologies llc	5.15%	290,463	SC 13G/A
Jun 10, 2022	kamin peter	11.1%	624,737	SC 13D/A
May 10, 2022	kamin peter	11.2%	624,737	SC 13D/A
Apr 21, 2022	kamin peter	11.2%	624,737	SC 13D/A
Feb 14, 2022	kubacki raymond c jr	6.0%	343,812	SC 13G/A
Feb 14, 2022	crawford investment counsel inc	4.81%	266,502	SC 13G/A

Recent SEC filings of Psychemedics Corp

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Psychemedics Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Psychemedics Corp News

Latest updates

Psychemedics Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	7.2%	5,357	4,998	5,704	5,537	5,859	5,703	6,516	6,513	6,508	6,436	6,673	6,087	5,713	5,335	5,174	3,314	7,537	8,715	9,852	9,289	9,822
Gross Profit	3.1%	2,122	2,058	2,091	2,059	2,205	2,246	2,332	2,273	2,441	2,185	3,075	2,436	2,568	1,277	1,133	-252	2,728	3,485	4,382	4,169	4,408
Operating Expenses	-8.1%	2,689	2,927	3,198	2,476	2,733	2,602	2,707	2,615	2,451	3,150	2,225	2,229	2,451	2,386	2,542	3,054	2,970	4,091	3,048	2,843	3,464
S&GA Expenses	-6.5%	692	740	723	746	789	782	791	813	806	849	652	656	642	719	896	856	1,106	1,203	1,238	1,088	1,129
R&D Expenses	-26.7%	209	285	275	286	298	323	328	357	318	313	244	293	280	299	305	345	331	354	393	400	420
EBITDA Margin	-7.9%	-0.04*	-0.03*	-0.01*	0.02*	0.04*	0.07*	0.00*	0.05*	0.07*	0.08*	0.12*	0.02*	-0.16*	-	-	-	-	-	-	-	-
Interest Expenses	0%	4.00	4.00	4.00	5.00	5.00	-3.00	17.00	9.00	10.00	10.00	12.00	14.00	14.00	15.00	17.00	20.00	23.00	12.00	9.00	21.00	17.00
Income Taxes	68.1%	116	69.00	992	-196	-149	326	-286	-13.00	17.00	-435	186	73.00	20.00	-577	-319	-1,295	-156	-72.00	663	580	343
Earnings Before Taxes	34.7%	-572	-876	-1,107	-922	-533	-362	-383	-351	56.00	-2,056	925	207	103	-1,120	-1,426	-3,345	-315	-602	1,340	1,348	970
EBT Margin	-3.5%	-0.16*	-0.16*	-0.13*	-0.09*	-0.07*	-0.04*	-0.11*	-0.05*	-0.03*	-0.03*	0.00*	-0.10*	-0.30*	-	-	-	-	-	-	-	-
Net Income	27.2%	-688	-945	-2,099	-726	-384	-688	-97.00	-338	39.00	-1,621	739	134	83.00	-543	-1,107	-2,050	-159	-530	677	768	627
Net Income Margin	-9.8%	-0.21*	-0.19*	-0.17*	-0.08*	-0.06*	-0.04*	-0.08*	-0.05*	-0.03*	-0.03*	0.02*	-0.06*	-0.19*	-	-	-	-	-	-	-	-
Free Cashflow	-189.4%	-473	529	-962	-959	-245	1,767	2,283	318	335	451	-442	643	-420	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.5%	11,152	12,326	14,104	16,386	17,907	18,732	20,478	20,450	20,968	21,552	23,633	24,587	24,380	24,003	23,980	25,776	25,210	27,531	26,784	25,135	25,529
Current Assets	-9.1%	6,187	6,805	7,872	8,228	9,535	9,964	10,724	10,902	10,525	10,285	11,672	11,736	10,627	9,598	8,831	9,754	10,778	12,851	13,487	13,323	13,473
Cash Equivalents	-27.6%	1,421	1,964	1,370	2,445	4,380	4,750	3,458	1,790	2,127	1,992	1,968	2,700	2,190	2,833	1,809	3,672	5,331	7,283	6,492	7,097	3,226
Net PPE	-100.0%	-	3,061	-	-	-	4,573	-	-	-	6,691	7,296	7,993	8,616	9,231	9,746	10,374	10,885	10,862	9,139	9,503	9,556
Liabilities	-13.8%	4,871	5,654	6,675	7,259	7,741	7,961	8,756	8,514	8,507	9,309	9,606	11,472	11,568	11,491	11,038	11,852	9,402	10,711	8,764	6,658	7,036
Current Liabilities	-11.1%	4,184	4,709	5,385	5,639	5,790	5,718	6,176	5,297	5,324	5,830	5,342	4,648	4,330	3,941	3,342	3,283	4,913	5,835	4,686	4,201	4,371
Long Term Debt	-	-	-	77.00	154	230	305	380	453	526	599	740	3,096	3,270	3,444	3,617	3,789	1,780	1,951	900	1,005	1,109
LT Debt, Current	-24.6%	230	305	302	299	297	294	360	461	563	664	696	693	691	688	685	683	680	678	416	416	416
LT Debt, Non Current	-	-	-	77.00	154	230	305	380	453	526	599	740	3,096	3,270	3,444	3,617	3,789	1,780	1,951	900	1,005	1,109
Shareholder's Equity	-5.9%	6,281	6,672	7,429	9,127	10,166	10,771	11,722	11,936	12,461	12,243	14,027	13,115	12,812	12,512	12,942	13,924	15,808	16,820	18,020	18,477	18,493
Retained Earnings	-4.1%	-17,461	-16,773	-15,828	-13,729	-12,602	-11,820	-10,733	-10,242	-9,511	-9,550	-7,650	-8,389	-8,523	-8,606	-8,063	-6,956	-4,906	-3,754	-2,232	-1,916	-1,690
Additional Paid-In Capital	0.8%	35,426	35,129	34,941	34,540	34,452	34,275	34,139	33,863	33,657	33,478	33,362	33,189	33,020	32,803	32,690	32,564	32,412	32,249	31,999	31,809	31,681
Accumulated Depreciation	1.3%	23,943	23,633	23,312	22,877	22,428	21,964	21.00	20,867	20,272	19,659	19,024	18,529	17,609	16,937	16,257	15,565	14,903	16,197	15,530	14,820	14,094
Shares Outstanding	0.0%	5,806	5,806	5,802	5,743	5,686	5,681	5,645	5,626	5,590	5,589	5,542	5,541	5,537	-	-	-	-	-	-	-	-
Float	-	-	-	-	22,100	-	-	-	26,900	-	-	-	29,000	-	-	-	22,000	-	-	-	37,000	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-171.5%	-473	662	-958	-959	-225	1,894	2,334	317	345	565	-388	650	-413	1,140	-1,494	-3,316	-413	948	1,671	1,322	368
Share Based Compensation	58.8%	297	187	401	143	177	178	277	238	179	179	178	169	217	114	126	160	163	250	190	161	158
Cashflow From Investing	0%	5.00	5.00	-43.00	-48.00	-73.00	-20.00	-98.00	-54.00	-36.00	-26.00	-118	-17.00	-59.00	56.00	-237	-344	-333	-565	-826	3,580	-112
Cashflow From Financing	-2.7%	-75.00	-73.00	-74.00	-928	-72.00	-582	-568	-600	-174	-515	-177	-172	-171	-172	-169	2,004	-1,162	321	-1,098	-1,130	-1,095
Dividend Payments	-	-	-	-	-	-	399	394	-	-	279	-	-	-	-	-	-	993	992	993	994	991

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PMD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 5,357	$ 5,859
Cost of revenues	3,235	3,654
Gross profit	2,122	2,205
Operating expenses:
General & administrative	1,788	1,646
Marketing & selling	692	789
Research & development	209	298
Total operating expenses	2,689	2,733
Operating (loss) income	(567)	(528)
Other (expense) income:
Settlement	(2)	0
Other	(3)	(5)
Total other (expense) income	(5)	(5)
(Loss) income before (benefit from) provision for income taxes	(572)	(533)
(Benefit from) provision for income taxes	116	(149)
Net loss	$ (688)	$ (384)
Basic net (loss) income per share (in dollars per share)	$ (0.12)	$ (0.07)
Weighted average common shares outstanding, basic and diluted (in shares)	5,806	5,685

PMD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 1,421	$ 1,964
Accounts receivable, net of allowance for doubtful accounts of $52 at June 30, 2023, and $87 at December 31, 2022	3,883	3,687
Prepaid expenses and other current assets	870	1,136
Income tax receivable	13	18
Total Current Assets	6,187	6,805
Fixed assets, net of accumulated amortization and depreciation of $22,877 at June 30, 2023, and $21,964 at December 31, 2022	2,759	3,061
Other assets	608	632
Operating lease right-of-use assets	1,598	1,828
Total Assets	11,152	12,326
Current Liabilities:
Accounts payable	1,131	752
Accrued expenses	1,780	2,604
Equipment financing debt	230	305
Current portion of operating lease liabilities	1,043	1,048
Total Current Liabilities	4,184	4,709
Long-term portion of operating lease liabilities	687	945
Total Liabilities	4,871	5,654
Commitments and Contingencies
Shareholders' Equity:
Common stock, $0.005 par value; 50,000 shares authorized; 6,411 and 6,349 shares issued and 5,743 and 5,681 shares outstanding, respectively	32	32
Additional paid-in capital	35,426	35,129
Accumulated deficit	(17,461)	(16,773)
Less - Treasury stock, at cost, 668 shares	(10,082)	(10,082)
Accumulated other comprehensive loss	(1,634)	(1,634)
Total Shareholders' Equity	6,281	6,672
Total Liabilities and Shareholders' Equity	$ 11,152	$ 12,326

About Psychemedics Corp

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, Fentanyl, and alcohol. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

CEO	Mr. Brian Hullinger
WEBSITE	psychemedics.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	133

Psychemedics Corp Frequently Asked Questions

What is the ticker symbol for Psychemedics Corp? What does PMD stand for in stocks?

PMD is the stock ticker symbol of Psychemedics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Psychemedics Corp (PMD)?

As of Fri May 17 2024, market cap of Psychemedics Corp is 14.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PMD stock?

You can check PMD's fair value in chart for subscribers.

What is the fair value of PMD stock?

You can check PMD's fair value in chart for subscribers. The fair value of Psychemedics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Psychemedics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Psychemedics Corp a good stock to buy?

The fair value guage provides a quick view whether PMD is over valued or under valued. Whether Psychemedics Corp is cheap or expensive depends on the assumptions which impact Psychemedics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PMD.

What is Psychemedics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PMD's PE ratio (Price to Earnings) is -3.36 and Price to Sales (PS) ratio is 0.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Psychemedics Corp's stock?

In the past 10 years, Psychemedics Corp has provided -0.136 (multiply by 100 for percentage) rate of return.